A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
第2相
完了
NCT06074562
| 対象疾患 | Diabetic Peripheral Neuropathy |
|---|
| 相 | 第2相 |
|---|
| スポンサー | Eli Lilly and Company |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 404 名 |
|---|
| 介入（薬剤） | Mazisotine |
|---|
| 開始日 | 2023年10月5日 |
|---|
| 完了日 | 2025年6月11日 |
|---|
| 結果公開日 | 2026年7月30日 |
|---|
概要
The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
Mean Change From Baseline in Average Pain Intensity (API) as Measured by Weekly Average of Numeric Rating Scale (NRS) - Bayesian Model Averaging (BMA) Dose-response Model
Baseline, Week 12 · score on a scale
| Placebo | NA score on a scale |
|---|
| Mazisotine 50 mg | NA score on a scale |
|---|
| Mazisotine 200 mg | NA score on a scale |
|---|
| Mazisotine 400 mg | NA score on a scale |
|---|
| Posterior Mean Difference | -0.01 (95% CI -0.27–0.24) |
|---|
Mean Change From Baseline in Average Pain Intensity (API) as Measured by Weekly Average of Numeric Rating Scale (NRS) - Frequentist Repeated Measures (FRM) Analysis
Baseline, Week 12 · score on a scale
| Placebo | -1.58 ± 0.154 score on a scale |
|---|
| Mazisotine 50 mg | -1.68 ± 0.217 score on a scale |
|---|
| Mazisotine 200 mg | -1.25 ± 0.208 score on a scale |
|---|
| Mazisotine 400 mg | -1.69 ± 0.214 score on a scale |
|---|
| p-value | 0.691 |
|---|
| LS Mean Difference | -0.10 (95% CI -0.61–0.40) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。